Carregant...
Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...
Guardat en:
| Publicat a: | Circ Rep |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The Japanese Circulation Society
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/ https://ncbi.nlm.nih.gov/pubmed/33693263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|